JP7838820B2 - Ｋｃｎｔ１阻害剤及び使用方法 - Google Patents

Ｋｃｎｔ１阻害剤及び使用方法

Info

Publication number
JP7838820B2
JP7838820B2 JP2022557683A JP2022557683A JP7838820B2 JP 7838820 B2 JP7838820 B2 JP 7838820B2 JP 2022557683 A JP2022557683 A JP 2022557683A JP 2022557683 A JP2022557683 A JP 2022557683A JP 7838820 B2 JP7838820 B2 JP 7838820B2
Authority
JP
Japan
Prior art keywords
mmol
alkyl
group
hydrogen
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022557683A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518838A5 (https=
JP2023518838A (ja
JPWO2021195066A5 (https=
Inventor
ボテージャ ガブリエル マルティネス
アンドリュー マーク グリフィン
Original Assignee
プラクシス プレシジョン メディシンズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プラクシス プレシジョン メディシンズ， インコーポレイテッド filed Critical プラクシス プレシジョン メディシンズ， インコーポレイテッド
Publication of JP2023518838A publication Critical patent/JP2023518838A/ja
Publication of JP2023518838A5 publication Critical patent/JP2023518838A5/ja
Publication of JPWO2021195066A5 publication Critical patent/JPWO2021195066A5/ja
Application granted granted Critical
Publication of JP7838820B2 publication Critical patent/JP7838820B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022557683A 2020-03-23 2021-03-23 Ｋｃｎｔ１阻害剤及び使用方法 Active JP7838820B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062993359P 2020-03-23 2020-03-23
US62/993,359 2020-03-23
PCT/US2021/023653 WO2021195066A2 (en) 2020-03-23 2021-03-23 Kcnt1 inhibitors and methods of use

Publications (4)

Publication Number Publication Date
JP2023518838A JP2023518838A (ja) 2023-05-08
JP2023518838A5 JP2023518838A5 (https=) 2024-04-03
JPWO2021195066A5 JPWO2021195066A5 (https=) 2024-04-03
JP7838820B2 true JP7838820B2 (ja) 2026-04-01

Family

ID=77892612

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022557683A Active JP7838820B2 (ja) 2020-03-23 2021-03-23 Ｋｃｎｔ１阻害剤及び使用方法

Country Status (11)

Country Link
US (1) US20230285377A1 (https=)
EP (1) EP4125831A4 (https=)
JP (1) JP7838820B2 (https=)
KR (1) KR20230005168A (https=)
CN (2) CN121868303A (https=)
AU (1) AU2021241530A1 (https=)
BR (1) BR112022019041A2 (https=)
CA (1) CA3176609A1 (https=)
IL (1) IL296649A (https=)
MX (2) MX2022011813A (https=)
WO (1) WO2021195066A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250172745A (ko) * 2019-05-03 2025-12-09 프락시스 프리시젼 메디신즈, 인크. Kcnt1 억제제 및 사용 방법
KR20220016086A (ko) * 2019-05-03 2022-02-08 프락시스 프리시젼 메디신즈, 인크. Kcnt1 억제제 및 사용 방법
JP7699836B2 (ja) 2020-02-28 2025-06-30 プラクシス プレシジョン メディシンズ， インコーポレイテッド Ｋｃｎｔ１阻害剤、および使用方法
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
WO2023211854A1 (en) * 2022-04-25 2023-11-02 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising a thiazole core and methods of use
WO2023211850A1 (en) * 2022-04-25 2023-11-02 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use
IL316283A (en) * 2022-04-25 2024-12-01 Praxis Prec Medicines Inc KCNT1 inhibitors comprising a pyrazole core and methods of use
EP4630399A1 (en) * 2022-12-05 2025-10-15 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising a phenyl, pyridine, or pyrimidine core and methods of use
TW202502311A (zh) * 2023-03-29 2025-01-16 美商默沙東有限責任公司 Il4i1抑制劑及其使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074501A1 (en) 2002-03-07 2003-09-12 Sds Biotech K.K. Substituted isoxazole alkylamine derivative and agri- and horticultural fungicide
JP2008503497A (ja) 2004-06-18 2008-02-07 ミレニアム ファーマシューティカルズ インク． 第Ｘａ因子阻害剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE478847T1 (de) * 2006-09-15 2010-09-15 Pfizer Substituierte pyridylmethylbicyclocarboxyamidverbindungen
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
TW201642855A (zh) * 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
EP3275440B1 (en) * 2015-03-25 2022-05-04 National Center for Geriatrics and Gerontology Novel oxadiazole derivative and pharmaceutical containing same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074501A1 (en) 2002-03-07 2003-09-12 Sds Biotech K.K. Substituted isoxazole alkylamine derivative and agri- and horticultural fungicide
JP2008503497A (ja) 2004-06-18 2008-02-07 ミレニアム ファーマシューティカルズ インク． 第Ｘａ因子阻害剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorganic & MedicinalChemistry Letters，2008年，Vol.18 No.19，p.5209-5212，DOI: 10.1016/j.bmcl.2008.08.080

Also Published As

Publication number Publication date
CN121868303A (zh) 2026-04-17
MX2022011813A (es) 2022-11-14
CN115715189B (zh) 2026-02-13
KR20230005168A (ko) 2023-01-09
EP4125831A4 (en) 2024-05-08
AU2021241530A1 (en) 2022-10-20
BR112022019041A2 (pt) 2022-12-27
EP4125831A2 (en) 2023-02-08
WO2021195066A2 (en) 2021-09-30
MX2026000122A (es) 2026-02-03
CN115715189A (zh) 2023-02-24
CA3176609A1 (en) 2021-09-30
US20230285377A1 (en) 2023-09-14
WO2021195066A3 (en) 2021-10-21
IL296649A (en) 2022-11-01
JP2023518838A (ja) 2023-05-08

Similar Documents

Publication Publication Date Title
JP7838820B2 (ja) Ｋｃｎｔ１阻害剤及び使用方法
EP2215049B1 (en) P2x3, receptor antagonists for treatment of pain
JP2022141773A (ja) 化合物及びその使用方法
JP7824664B2 (ja) Ｋｃｎｔ１阻害剤及び使用方法
JP4576386B2 (ja) アルツハイマー病治療用のベンジルエーテルおよびベンジルアミノ系β−セクレターゼ阻害薬
JP7699836B2 (ja) Ｋｃｎｔ１阻害剤、および使用方法
US20240043415A1 (en) Kcnt1 inhibitors and methods of use
EP4329735B1 (en) Kcnt1 inhibitors and methods of use
AU2021227935B2 (en) KCNT1 inhibitors and methods of use
HK40089122A (zh) Kcnt1抑制剂和使用方法
JP2025514140A (ja) ピラゾールコアを含むｋｃｎｔ１阻害剤及び使用方法
EP4630399A1 (en) Kcnt1 inhibitors comprising a phenyl, pyridine, or pyrimidine core and methods of use
WO2023211854A1 (en) Kcnt1 inhibitors comprising a thiazole core and methods of use
WO2023122152A1 (en) Kcnt1 inhibitors and methods of use
WO2023211850A1 (en) Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use
WO2022231872A1 (en) Kcnt1 inhibitors and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260312

R150 Certificate of patent or registration of utility model

Ref document number: 7838820

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150